Paper Details

  1. Home
  2. Paper Details

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.

Author: AscariE, CassanoE, DanovaM, MerliniG, MontecuccoC, RiccardiA, UcciG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 75 patients with previously untreated multiple myeloma found that melphalan and prednisone (MPH-P) were more effective in inducing remission and prolonging survival than Peptichemio, Vincristine, and prednisone (PTC-VCR-P).
Paper Details　
Original Abstract of the Article :
Seventy-five patients with previously untreated multiple myeloma were randomly treated with the association of Peptichemio, Vincristine and prednisone (PTC-VCR-P) or of melphalan and P (MPH-P) for first induction therapy. After induction, all responsive patients received MPH and P until relapse, whi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0277-5379(86)90364-0

データ提供：米国国立医学図書館（NLM）

Comparing Treatment Options for Multiple Myeloma: A Tale of Two Regimens

In the vast desert of multiple myeloma research, we are always searching for oases of effective treatments. This study delves into the effectiveness of two induction therapies: Peptichemio, Vincristine, and prednisone (PTC-VCR-P) versus melphalan and prednisone (MPH-P). Like a wise traveler choosing the best route across a vast expanse, researchers compared the efficacy of these regimens in 75 patients with previously untreated multiple myeloma. They carefully observed the response rates, duration of response, and overall survival of patients in each group, analyzing the data like grains of sand under a magnifying glass.

A Tale of Two Responses

The results revealed that PTC-VCR-P and MPH-P produced similar response rates, showing no significant difference. However, the duration of response was notably different, with MPH-P outperforming PTC-VCR-P. This is like comparing two types of camel caravans: one might have a faster start but the other might endure longer and reach the desired destination with more ease. Furthermore, the survival rate of patients receiving MPH-P was significantly better than those receiving PTC-VCR-P.

Choosing the Right Path: Considering the Stage

The study also evaluated the effectiveness of the treatments in different stages of multiple myeloma. While both regimens were comparable in stage I and II, PTC-VCR-P showed a greater response rate in stage III. This suggests that like a desert traveler choosing a suitable route based on the terrain, selecting the right treatment regimen may depend on the stage of the disease. The study found a trend towards longer survival for stage III patients receiving PTC-VCR-P, but this trend was not statistically significant.

Dr. Camel's Conclusion

This study provides valuable insights into the effectiveness of different treatment options for multiple myeloma. It highlights the importance of considering the stage of the disease when choosing a treatment regimen. Further research is needed to explore the long-term impact of these treatments and identify the best strategies for managing this challenging disease.

Date :
  1. Date Completed 1986-11-24
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

3770037

DOI: Digital Object Identifier

10.1016/0277-5379(86)90364-0

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.